Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 3(64), 2020
DOI: 10.1128/aac.01982-19
Links
Tools
Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome
Journal article published in 2020 by
Iain J. Abbott 
,
Elke van Gorp,
Rixt A. Wijma,
Joseph Meletiadis,
Jason A. Roberts ,
Johan W. Mouton ,
Anton Y. Peleg
,
Elke van Gorp,
Rixt A. Wijma,
Joseph Meletiadis,
Jason A. Roberts ,
Johan W. Mouton ,
Anton Y. Peleg
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Data provided by 
Abstract
Oral fosfomycin trometamol is licensed as a single oral dose for the treatment of uncomplicated urinary tract infections, with activity against multidrug-resistant uropathogens. The impact of interindividual variability in urinary concentrations on antimicrobial efficacy, and any benefit of giving multiple doses, is uncertain.